SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Tao Fu, Emmanouil P. Pappou, Angela A. Guzzetta, Marilia de Freitas Calmon, Lifeng Sun, Alexander Herrera, Fan Li, Christopher L. Wolfgang, Stephen B. Baylin, Christine A. Iacobuzio-Donahue, Weidong Tong, Nita Ahuja, IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers, Annals of Surgery, 2016, 263, 2, 337

    CrossRef

  2. 2
    Michele Ghidini, Nicola Personeni, Silvia Bozzarelli, Marina Baretti, Gianluca Basso, Paolo Bianchi, Maria Chiara Tronconi, Tiziana Pressiani, Fabio Grizzi, Laura Giordano, Alberto Malesci, Marco Alloisio, Luigi Laghi, Armando Santoro, Lorenza Rimassa, KRAS mutation in lung metastases from colorectal cancer: prognostic implications, Cancer Medicine, 2016, 5, 2
  3. 3
    Cetin Ordu, Nalan A. Selcuk, Cengiz Akosman, Orhan Onder Eren, Elif C. Altunok, Turkay Toklu, Basak Oyan, Comparison of Metabolic and Anatomic Response to Chemotherapy Based on PERCIST and RECIST in Patients with Advanced Stage Non-small Cell Lung Cancer, Asian Pacific Journal of Cancer Prevention, 2015, 16, 1, 321

    CrossRef

  4. 4
    Bert Gold, Milena Cankovic, Larissa V. Furtado, Frederick Meier, Christopher D. Gocke, Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility?, The Journal of Molecular Diagnostics, 2015, 17, 3, 209

    CrossRef

  5. 5
    M. López-Gómez, J. Moreno-Rubio, I. Suárez-García, P. Cejas, R. Madero, E. Casado, A. M. Jiménez, M. Sereno, C. Gómez-Raposo, F. Zambrana, M. Merino, D. Fernández-Luengas, J. Feliu, Gene expression differences in primary colorectal tumors and matched liver metastases: chemotherapy related or tumoral heterogeneity?, Clinical and Translational Oncology, 2015, 17, 4, 322

    CrossRef

  6. 6
    Georgios D Lianos, Georgios K Glantzounis, Alberto Mangano, Stefano Rausei, Dimitrios H Roukos, Colorectal liver metastases guidelines, tumor heterogeneity and clonal evolution: can this be translated to patient benefit?, Future Oncology, 2014, 10, 10, 1723

    CrossRef

  7. 7
    Kjetil Søreide, Oddvar M. Sandvik, Jon A. Søreide, KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: A biomarker of cancer biology or a byproduct of patient selection?, Cancer, 2014, 120, 24
  8. 8
    L. Ung, A. K.-Y. Lam, D. L. Morris, T. C. Chua, Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review, Clinical and Translational Oncology, 2014, 16, 5, 425

    CrossRef

  9. 9
    Georgios D Lianos, Alberto Mangano, Stefano Rausei, Christos Katsios, Dimitrios H Roukos, Tumor heterogeneity-based resistance guides personalized cancer medicine, Future Oncology, 2014, 10, 12, 1889

    CrossRef

  10. 10
    Aaron J Scott, Stephen Leong, Wells A Messersmith, Christopher H Lieu, A moving target: challenges in treatingBRAF-mutant colorectal cancer, Colorectal Cancer, 2013, 2, 3, 197

    CrossRef

  11. 11
    Enikő Orosz, István Ember, Katalin Gombos, László Tóth, Ádám Tarpay, Ákos Pap, Szabolcs Ottó, Alternatives for the Intensive Follow-Up After Curative Resection of Colorectal Cancer. Potential Novel Biomarkers for the Recommendations, Pathology & Oncology Research, 2013, 19, 4, 619

    CrossRef

  12. 12
    Christoph A. Klein, Selection and adaptation during metastatic cancer progression, Nature, 2013, 501, 7467, 365

    CrossRef